$ODT on NASDAQ
January 07, 2022
Odonate Announces Expected Delisting of Its Stock
November 17, 2021
Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan
November 10, 2021
Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021
July 27, 2021
Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021
May 14, 2021
Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021
March 22, 2021
Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel
February 23, 2021
Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020
December 11, 2020
Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)
December 07, 2020
Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel Monotherapy in Patients with Metastatic Breast Cancer
December 01, 2020
Odonate Therapeutics to Host Virtual Investor and Analyst Event on December 11, 2020
October 28, 2020
Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020
October 05, 2020
Results of CONTESSA, a Phase 3 Study of Tesetaxel in the Treatment of Patients with Metastatic Breast Cancer, to Be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)
August 27, 2020
Odonate Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
August 26, 2020
Odonate Therapeutics Announces Public Offering of Shares of Common Stock
August 24, 2020
Odonate Therapeutics Announces Positive Top-line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer
August 21, 2020
Odonate Therapeutics to Hold Conference Call on Monday, August 24, 2020 at 8:30 a.m. ET
July 30, 2020
Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020
May 29, 2020
Odonate Therapeutics to Present at the Jefferies Virtual Healthcare Conference
April 28, 2020
Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2020
February 20, 2020
Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2019
November 06, 2019
Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019
October 21, 2019
Odonate Therapeutics Announces Completion of Enrollment in CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer
July 24, 2019
Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2019
June 26, 2019
Odonate Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
June 25, 2019
Odonate Therapeutics Announces Public Offering of Shares of Common Stock
June 03, 2019
Independent Data Monitoring Committee (IDMC) Recommends CONTESSA Continue with No Modifications following Planned Interim Efficacy Futility Analysis
May 29, 2019
Odonate Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
April 25, 2019
Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019
- No Recent Filings Found.
